Research on Our Drug Candidate S-003 Published in an International Academic Journal

Research on our SO-003 compound (https://socium.co.jp/drug_discovery/), which patent was jointly filed by SOCIUM Co., Ltd. (https://socium.co.jp), the School of Pharmacy at Nanjing Medical University, and our collaborative partner Suzhou Platinum Pharmaceutical Technology Co., Ltd. (see our NEWS: July 22, 2025), has been published in Results in Chemistry (impact factor 4.2), (Available online April 27, 2026, https://doi.org/10.1016/j.rechem.2026.103362).

This paper details research on the chemical synthesis of compound SO-003, led by Dr. Dongyin Chen (Associate Professor at the School of Pharmacy and Nanjing Medical University, and CEO of Suzhou Brainlight Biomedical Technology Co., Ltd). The investigator-initiated clinical trial for SO-003 has already commenced (see our NEWS: December 1, 2025), and this study not only supports the jointly filed patent but also partially complements this trial.

Our company is advancing the discovery and development of therapeutic leads using our proprietary drug repositioning platform. Together with the investigator-initiated SO-002 trial currently underway at Huaxi Hospital of Sichuan University (see our NEWS: November 17, 2025), this paper demonstrates the platform potential not only for discovering therapeutic leads for rare diseases using approved drugs but also for discovering new compound leads through compound synthesis and development.

We will continue to steadily build upon the achievements on our potential for drug candidate discovery and development, striving to realize our vision of “Drug discovery for patients with no drug, Drug discovery for patients with ineffective drug”.